Alzheimer's research at risk as diagnoses rise
More than 7 million American seniors now live with Alzheimer's disease — the highest number ever recorded, according to 2025 data shared in a new Alzheimer's Association report.
Why it matters: As Alzheimer's diagnoses rise, the federal funding for medical research that's critical to preventing and treating it is at risk of being cut.
State of play: Over 17,300 Californians die from Alzheimer's every year, but addressing cognitive decline early can help stave off the disease.
That's especially important with San Diego County's growing senior population — about 16% of residents.
Zoom in: The odds of being diagnosed with Alzheimer's is higher in San Diego than many other parts of the country, at least in part because of the local hospital system.
That doesn't necessarily mean more people have the disease, but more thorough diagnosing can lead to more cases, better care, new tests and treatments.
Between the lines: UC San Diego has the top NIH-funded neuroscience department in the country, and the university's Alzheimer's Disease Research Center is developing potential treatments, monitoring drug safety and running clinical trials aimed at prevention.
That federal funding is at risk of being pulled, which center director Jim Brewer has said would "absolutely cut the knees out" and could delay progress in addressing the disease, particularly through clinical trials.
The latest: The FDA on Friday cleared the first blood test to help diagnose the disease, which could help with early detection.
By the numbers: About 12% of Californians over 65 are living with Alzheimer's, per 2020 data in the report.
That's almost 720,000 people.
At 15%, Imperial County had the ninth-highest prevalence in the country.
Zoom out: The highest rates of seniors with Alzheimer's are in D.C. (16.8%), Maryland (12.9%) and New York (12.7%), according to the association.
Nearly two-thirds of all Americans diagnosed with the disease are women, per data cited in the report. UCSD researchers are currently trying to figure out why.
Warning signs to watch for in high-risk age groups:
Trouble finding the right word.
Difficulty judging distances.
Misplacing things and struggling to retrace steps.
Be smart: Keeping your brain on its toes, so to speak, can help prevent dementia.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
2 hours ago
- The Hill
Thanks to imported drugs, America has lost control of its medicine cabinet
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicines. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe. At the root of it is a hard truth: We no longer have control of the medicines we depend on every day. In 2002, America manufactured 83.7 percent of the pharmaceuticals it consumed. By 2024, that number had dropped to just 37.1 percent. Meanwhile, the U.S. pharmaceutical trade deficit has soared, reaching a record $118.3 billion in 2024. We didn't just outsource manufacturing — we outsourced the sovereignty and safety of our health care system. This means that nearly two-thirds of America's pharmaceutical supplies are now imported. Most critical medications, such as generic drugs, now come from China and India. China controls 80 to 90 percent of the global supply of active pharmaceutical ingredients — the chemical building blocks of modern medicine. Even drugs labeled 'Made in the USA' often chemically originate in China. And India, which produces about half of America's finished generic drugs, relies on China for up to 80 percent of its active pharmaceutical not a supply chain — it's a ticking time something goes wrong, American patients suffer. In 2023, the Food and Drug Administration shut down a single Indian plant responsible for 50 percent of the U.S. supply of cisplatin, a critical chemotherapy drug, after uncovering a 'cascade of failure' in safety practices and shredded documents soaked in acid. With no domestic backup, patients nationwide had their treatments delayed. That wasn't a fluke. 40 percent of U.S. generic drugs have only one FDA-approved manufacturer. Because of that single chokepoint, when one factory fails, the whole system can crack. We are now seeing widespread drug shortages across the medical system. Hospital pharmacists report an average of 301 critical drug shortages at any given time. And 85 percent say these shortages are moderately or critically affecting care. Doctors often lack crucial medicines such as antibiotics, sedatives and cancer drugs. These aren't obscure drugs. They're foundational medicines. But America no longer makes them. Even when imported drugs do arrive, they're not always safe. A 2025 study found that Indian generics are 54 percent more likely to cause serious side effects than their U.S.-made counterparts. Indian factory violations have also been tied to at least eight U.S. patient deaths. China's record is equally disturbing. In 2008, dozens of Americans died after receiving contaminated heparin from Chinese suppliers. This isn't what the American people want. In a national survey, 85 percent of hospital pharmacists said they would pay more for safer generics. But under today's rules, price overshadows quality. Hospitals have little oversight of drug quality — and foreign producers face few consequences for cutting corners. Even the federal government is flying blind. A 2023 Department of Defense review found that 22 percent of essential military-use drugs had unknown ingredient sourcing. That's a national security April, the Trump administration took a necessary step by launching an investigation into generic pharmaceutical imports that correctly frames the issue as a national security threat. But that recognition alone isn't enough. To address this crisis, Washington should impose targeted tariffs on generic drugs from adversarial nations. It must also rebuild domestic pharmaceutical production through tax credits and long-term contracts. America urgently needs full transparency in drug labeling to disclose where drugs and their ingredients are made. The FDA must step up — with stronger enforcement abroad and a ban on imports from repeat safety violators. And to secure critical ingredients during market disruptions, Washington must pursue a long-term vision that includes a 'strategic pharmaceutical reserve.' This isn't just protectionism. It's a restoration of America's medical security. No nation can call itself sovereign if it can't produce its own medicines, and no patient is safe if their health care depends on quality control in a factory 8,000 miles decades, we were told that offshoring production would make things cheaper, smoother and more efficient. But America can no longer depend on unstable foreign suppliers. It's time to restore our pharmaceutical independence and take back control of our medicine cabinet. Andrew Rechenberg is an economist at the Coalition for a Prosperous America.
Yahoo
2 hours ago
- Yahoo
FDA-Approved Sleeping Pill Slows Alzheimer's Tangles in Pre-Clinical Trial
A drug used to treat insomnia has protected mice against the buildup of the tau protein found to clump abnormally in neurodegenerative diseases like Alzheimer's. This could lead to new ways to help slow the progress of these diseases. An increasing number of people are facing cognitive decline personally or in their loved ones. There are almost 10 million new cases of dementia globally each year, and despite decades of research, there are still few treatment options that provide clear benefits. So due to the links between Alzheimer's and poor sleep, Washington University neurologist Samira Parhizkar and colleagues investigated a central nervous system depressant, lemborexant, that was approved for use as a sleep aid by the FDA in December 2019. "We have shown that lemborexant improves sleep and reduces abnormal tau, which appears to be a main driver of the neurological damage that we see in Alzheimer's and several related disorders," explains Washington University neurologist David Holtzman. The role of amyloid beta proteins in Alzheimer's has been controversial, but they're not the only proteins implicated in the disease. Tau proteins normally contribute to the structure of brain cells, but past research has linked abnormal ones with the rate of brain atrophy in animal models. "The antibodies to amyloid that we now use to treat patients with early, mild Alzheimer's dementia are helpful, but they don't slow the disease down as much as we would like," says Holtzman. "We need ways to reduce the abnormal tau buildup and its accompanying inflammation, and this type of sleep aid is worth looking at further." But when the researchers compared lemborexant with another sleep aid, zolpidem, the results were unexpected. Mice receiving lemborexant retained up to 40 percent more volume in their memory-forming hippocampus than those who received zolpidem or no sleep aid at all. "What was surprising was that these effects were not seen with a standard sleep drug like zolpidem, which increases NREM sleep similarly to lemborexant," Parhizkar told Eric Dolan at PsyPost. "This suggests that the benefit is not just about more sleep, but rather how that sleep is promoted." The two sleep drugs work on different mechanisms, and that seems to be key to the protective effects. Lemborexant blocks orexin, a neuropeptide that regulates the sleep cycle, and when the team genetically knocked out orexin receptor 2 in mice, it reduced the buildup of tau in their brains. Strangely, though, the protective results of lemborexant were only seen in male mice, even though females were also tested. What's more, mouse studies don't always produce the same results in humans. Lemborexant has only been approved for short-term use in humans, so its long-term impacts as well as effectiveness in tau reduction still need to be investigated. While many questions remain to be answered, if the results seen in this study hold true, the researchers hope early intervention with a drug like lemborexant could potentially delay the progression of neurodegeneration. This research was published in Nature Neuroscience. Risk of Sleep Breathing Disorder Set to Rise 45% by End of Century Breakthrough: FDA Approves Injection to Prevent HIV Is It Gastro or Food Poisoning? Here's A Guide to Your Upset Stomach
Miami Herald
4 hours ago
- Miami Herald
Some Johns Hopkins, UMD research stopped after Trump cuts. Others are scrambling to resume
BALTIMORE - Some Maryland university research projects on the Trump administration's chopping block have been fully discontinued, while others are scrambling to resume after a pause in funding. Johns Hopkins has lost more than $800 million in federal grant money. The University of Maryland lost tens of millions of dollars. But some cuts have been blocked by legal challenges, though litigation is ongoing. Researchers describe disappointment and uncertainty as they determine how to move forward. Alternative funding has been secured for a clinical trial in Bangladesh aimed at managing life-threatening diarrheal diseases in children, which was previously halted because of U.S. Agency for International Development funding cuts. The work has yet to resume. "It just takes a long time to rebuild the teams and get things in place again to start," said Judd Walson, chair of the Department of International Health at Johns Hopkins University, which partnered on the project. "The disruptions that are happening are really catastrophic." Over the past several weeks, 17 NIH awards have been terminated or had an unclear status, including two training awards supporting doctoral-level researchers, Walson said. "We're not getting a lot of communication, so it's a little bit hard to say exactly what the status of some of these awards are," he said. The National Institutes of Health didn't respond to questions about funding cuts to Maryland research institutions. In a lawsuit challenging NIH research cuts, lawyers for the federal government wrote in a recent court filing that its terminations of grants for DEI-related studies were "sufficiently reasoned," and that the NIH has "broad discretion" to decide what grants to provide. Johns Hopkins is a plaintiff in two lawsuits involving caps on reimbursement of indirect costs for research - one challenging the NIH and the other against the Department of Defense. The latter suit also lists the University of Maryland, College Park, as a plaintiff. Both schools have also filed a brief in support of a lawsuit filed by Harvard University against the Trump administration's funding cuts. New grant terminations have been arriving "nearly every week," Johns Hopkins University said in a recent update published on its website. There's also been a nearly two-thirds decrease in new awards compared with last year, the university said. Johns Hopkins atmosphere and ocean sciences researcher Darryn Waugh was disappointed upon receiving notice that his NASA grant to study air pollution in Baltimore was canceled by the Trump administration. The termination came as a result of President Donald Trump's executive order, "Ending Radical and Wasteful Government DEI Programs and Preferencing." "It wasn't clear to me that this actually falls under this diversity, equity, inclusion," Waugh said. "It was research that I think we still wanted to do - to understand how the air pollution varies through the city - and the environmental justice was only actually a relatively small component of it." Waugh was working through the second year of a three-year grant, totaling $1,465,950. "We've got kind of a preliminary analysis," he said, regarding the research. "But to get anything conclusive, we would need more than one year of funding." Waugh said he intends to find ways of continuing the research without the NASA grant. Daniel Mullins, at the University of Maryland School of Pharmacy, had a grant canceled for a "Health Equity Research Hub," which examined how to encourage greater participation in health-related research. Mullins said the loss of the grant affected five positions, and the individuals will be removed from the university because of lack of funding. He added that the termination stated that the grant was DEI-related, which he disputes. "I think under the DEI umbrella, a lot of times, the government will refer to it as just one racial ethnic group," he said. "We've worked in different geographies, in different racial and ethnic populations, but what's cool about what we do is it really does apply to all patients in all populations." Mullins said his research group has additional funding from other agencies and is writing new proposals. Walson said social determinants of health - involving factors like poverty and other "inequities" - are "foundational to our understanding of health." "So the idea that we would not be able to pursue work that focuses on identifying and managing those particular issues, which are the underlying, core issues at the heart of health issues, is really challenging," Walson said. The Trump administration's cuts have had an ieffect across the world. Walson said it's estimated the cuts will result in hundreds of thousands of deaths globally, and could eventually lead to millions of deaths over the next couple of years. Secretary of State Marco Rubio has said it's "a lie" that people have died because of USAID cuts. During a congressional hearing in May, Rubio said the U.S. is the world's "largest humanitarian provider." "I would argue: How many people die because China hasn't done it?" he said. "How many people have died because the U.K. has cut back on spending and so has other countries?" Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
